Asylia Diagnostics BV is presenting results
EIT Health Catapult
On Wednesday December 1st at 1pm, our CEO Andrey Khmelevskiy will represent Asylia Diagnostics during the EIT Health Catapult semifinals in the Biotech category.
We are truly humbled to be part of an incredible cohort, together with 13 other companies: AddaxBiosciences, APLEX Bio, ARTHEx Biotech, Bioadhesive Ophthalmics, Enantis, Finnadvance, myNEO - Personalised platform for cancer, OmicEra Diagnostics, Onena Medicines, Limula, Renovos Biologics Limited, SideROS and SolasCure.
Curing cancer with the power of AI
Our CEO Andrey Khmelevskiy had an interview with Sofie Van Poucke for Invest in Flanders . They discussed why what we do in Asylia Diagnostics BV is important for clinicians and cancer patients worldwide and why we felt that Flanders is the perfect place for us to grow the biotech company. We are immensely grateful to Flanders biotech community and people who all helped us to learn about the unique Flanders ecosystem. This ecosystem is not only incredibly professional but also so welcoming to newcomers like us.
International cancer cluster showcase
After #ICCS2020, we are pleased to announce that Asylia Diagnostics BV Andrey Khmelevskiy has recently received an EIT Health and Team Bedrijfstrajecten - VLAIO non-dilutive grant of 628K to further support the development of its innovative diagnostics technology!
Also selected to join the prestigious MassBio MassCONNECT program, where they will have access to mentoring & business support from industry experts.